Compare Abbott Laboratories (ABT) vs Expensify Inc (EXFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Expensify Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Expensify Inc trades at $1.88 (market cap $179.86M). The key difference: Abbott Laboratories is far larger — about 928.2× Expensify Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| ABT | EXFY | |
|---|---|---|
Market Cap | $166.94B | $179.86M |
Sector | Health | Technology |
52-Week High | $136.62 | $2.51 |
52-Week Low | $82.57 | $0.75 |
Enterprise Value | $193.69B | $118.89M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Expensify (EXFY) trades at $1.71, up 0.59% with a bullish technical signal from moving averages. The company maintains strong revenue around $142M but continues to report net losses, with a negative net income margin of -14.68%. Recent developments include AI product expansions and a $25M stock buyback program. Analyst sentiment is mixed with a 44% buy rating, while technical indicators show RSI levels suggesting potential overbought conditions near-term.
The outlook remains challenging with persistent profitability issues despite stable revenue. Investment opportunity exists in the company's AI initiatives and market positioning, but risks include ongoing losses, competitive pressure, and execution challenges. The stock's high P/E ratio of 258.82 reflects growth expectations that must materialize to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
